Sumanta Kumar Pal MDClinical Professor, Department of Medical Oncology & Therapeutics Research; Co-Director, Kidney Cancer Program, City of Hope, Duarte, California
Dr. Sumanta (Monty) Pal is a medical oncologist and an internationally recognized leader in the area of genitourinary cancers. He is a Clinical Professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California, where he is co-director of the kidney cancer program and heads up the kidney and bladder cancer disease team at that institution. Dr. Pal entered medical school at the age of 17, and received his MD from the UCLA School of Medicine, where he developed his interest in cancer research. After residency training in internal medicine at the UCLA Medical Center in Los Angeles, he completed a fellowship in medical oncology at City of Hope Comprehensive Cancer Center, where he has remained on faculty since 2009.
Over that time, he has published more than 400 PubMed-cited articles, which have been featured in prominent journals, including The Lancet, Nature Medicine, Cancer Discovery, Journal of Clinical Oncology, The Lancet Oncology, and European Urology, and has presented his work at numerous international meetings. His goal is to translate laboratory discoveries as quickly and efficiently as possible into tangible benefits for patients. Dr. Pal is the lead investigator on multiple trials, ranging from early phase I experiences to late phase III studies. He has received grants from the National Institute of Health, the Comprehensive Cancer Network, SWOG Cancer Research Network, and multiple other leading entities in support of his research.
Clinical Professor, Department of Medical Oncology & Therapeutics Research; Co-Director, Kidney Cancer Program, City of Hope, Duarte, California
MD: UCLA School of Medicine, Los Angeles, California
Fellowship (hematology/oncology): City of Hope/Harbor-UCLA Medical Center, Los Angeles, California
Genitourinary cancers; translational science; microbiome
Sumanta Kumar Pal, MD, serves as a consultant to Roche. He also receives institutional research funds from Roche, Genentech, Exelixis, Eisai, and Pfizer.
Recent Contributions to PracticeUpdate:
- Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy for Advanced ccRCC
- Adjuvant Pembrolizumab for Post-Nephrectomy RCC
- Association Between DepOR and Clinical Outcomes in Previously Untreated RCC
- Durvalumab Alone or With Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer
- ASCO 2022: Abstract Recommendations From Dr. Sumanta Pal for Renal Cell and Urothelial Carcinoma
- Nivolumab Plus Ipilimumab With or Without Live Bacterial Supplementation in mRCC
- Molecular Alterations Across Metastatic Sites Among Patients With RCC
- Neoadjuvant Avelumab/Axitinib for Patients With Localized RCC
- Nivolumab Plus Axitinib for Advanced RCC
- Trastuzumab Deruxtecan Plus Nivolumab Among Patients With HER2-Expressing Urothelial Carcinoma